HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Safety of Statin Pretreatment in Intravenous Thrombolysis for Acute Ischemic Stroke.

AbstractBACKGROUND AND PURPOSE:
A recent meta-analysis investigating the association between statins and early outcomes in acute ischemic stroke (AIS) patients treated with intravenous thrombolysis (IVT) indicated that prestroke statin treatment was associated with increased risk of 90-day mortality and symptomatic intracranial hemorrhage. We investigated the potential association of statin pretreatment with early outcomes in a large, international registry of AIS patients treated with IVT.
METHODS:
We analyzed prospectively collected data from the Safe Implementation of Treatments in Stroke-East registry (SITS-EAST) registry on consecutive AIS patients treated with IVT during an 8-year period. Early clinical recovery within 24 hours was defined as reduction in baseline National Institutes of Health Stroke Scale score of ≥10 points. Favorable functional outcome at 3 months was defined as modified Rankin Scale scores of 0 to 1. Symptomatic intracranial hemorrhage was diagnosed using National Institute of Neurological Disorders and Stroke, European-Australasian Acute Stroke Study-II and SITS definitions.
RESULTS:
A total of 1660 AIS patients treated with IVT fulfilled our inclusion criteria. Patients with statin pretreatment (23%) had higher baseline stroke severity compared with cases who had not received any statin at symptom onset. After adjusting for potential confounders, statin pretreatment was not associated with a higher likelihood of symptomatic intracranial hemorrhage defined by any of the 3 definitions. Statin pretreatment was not related to 3-month all-cause mortality (odds ratio, 0.92; 95% confidence interval, 0.57-1.49; P=0.741) or 3-month favorable functional outcome (odds ratio, 0.81; 95% confidence interval, 0.52-1.27; P=0.364). Statin pretreatment was independently associated with a higher odds of early clinical recovery (odds ratio, 1.91; 95% confidence interval, 1.25-2.92; P=0.003).
CONCLUSIONS:
Statin pretreatment seems not to be associated with adverse outcomes in AIS patients treated with IVT. The effect of statin pretreatment on early functional outcomes in thrombolysed AIS patients deserves further investigation.
AuthorsGeorgios Tsivgoulis, Pavla Kadlecová, Adam Kobayashi, Anna Czlonkowska, Miroslav Brozman, Viktor Švigelj, Laszlo Csiba, Janika Kõrv, Vida Demarin, Aleksandras Vilionskis, Dalius Jatuzis, Aristeidis H Katsanos, Jobst Rudolf, Yakup Krespi, Robert Mikulik
JournalStroke (Stroke) Vol. 46 Issue 9 Pg. 2681-4 (Sep 2015) ISSN: 1524-4628 [Electronic] United States
PMID26173726 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2015 American Heart Association, Inc.
Chemical References
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
Topics
  • Administration, Intravenous
  • Aged
  • Aged, 80 and over
  • Brain Ischemia (drug therapy)
  • Europe
  • Female
  • Follow-Up Studies
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage, adverse effects)
  • Intracranial Hemorrhages (chemically induced)
  • Male
  • Middle Aged
  • Mortality
  • Outcome Assessment, Health Care
  • Registries
  • Severity of Illness Index
  • Stroke (drug therapy)
  • Thrombolytic Therapy (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: